A Pharmacokinetic Study to Access How the Body Absorbs and Removes Linifanib in Male Patients With Advanced Solid Tumors.

Abbott

Status and phase

Terminated

Phase 1

Conditions

Advanced Solid Tumors

Treatments

Drug: [14C]linifanib

Drug: ABT-869, linifanib

Study type

Interventional

Funder types

Industry

Identifiers

NCT01286974

M10-966

Details and patient eligibility

About

A pharmacokinetic study to access how the body absorbs and removes linifanib in male patients with advanced solid tumors.

Full description

This study is designed to assess the mass balance of [14C]linifanib and the metabolic profiles of linifanib in 4 subjects with advanced solid tumors following a single oral dose. Subjects may continue on linifanib after completion of the metabolism study. The results of this study will determine the exposure of major metabolites and excretion pathway(s) of the parent drug and metabolites of linifanib in humans.

Enrollment

3 patients

Sex

Male

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

Subject must be >/= 18 years of age.
Subject must have a histologically or cytologically confirmed non-hematologic malignancy.
Eastern cooperative Oncology Group (ECOG) Performance Score of 0 to 2.
Subject must have adequate bone marrow, renal and hepatic function.
Subject must have Partial Thromboplastin Time (PTT) </= 1.5 x Upper Limit of Normal (ULN) and International Normalized Ratio (INR) </= 1.5.
Subject must be capable of understanding and complying with parameters as outlined in the protocol and able to sign the informed consent.

Exclusion Criteria

Subject has received previous administration of a radiolabeled research substance within 12 months prior to Study Day 1 or exposure to significant radiation (e.g., barium meal, etc.) within the past 3 months or within a period defined by 5 half-lives, whichever is shorter, prior to Study Day 1.
Subject has received anti-cancer therapy including investigational agents, cytotoxic chemotherapy, radiation, hormonal or biologic therapy within 21 days or within a period defined by 5 half-lives, whichever is shorter, prior to Study Day 1.
Subject is currently using a known inhibitor (e.g., ketoconazole) or inducer (e.g., rifampin) of cytochrome P450 3A (CYP3A) within 1 month prior to Study Day 1.
Subject has not recovered to less than or equal to grade 1 clinically significant adverse effects/toxicities of the previous therapy.
Subject has undergone major surgery within 21 days of Study Day 1.
The subject has brain or meningeal metastases.
The subject has non-small cell lung cancer (NSCLC) with a predominant squamous cell histology.
Subject is receiving therapeutic anticoagulation therapy.
Subject has a history of/or currently exhibits clinically significant events of bleeding (e.g., hemoptysis).
Subject has proteinuria Common Terminology Criteria (CTC) Grade > 2 at baseline.
Subject currently exhibits symptomatic or persistent, uncontrolled hypertension.
Subject has a history of myocardial infarction within 6 months.
Subject has known autoimmune disease with renal involvement.
Subject is receiving combination anti-retroviral therapy for human immunodeficiency virus (HIV).
Clinically significant uncontrolled conditions/medical symptoms.
Subject has a documented left ventricular (LV) ejection fraction < 50%.
Subject has previously received linifanib.